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Abstract
Objective: Although monoammonium glycyrrhizinate/glycine/DL-methionine (MG) combination tablets have been
widely used widely for the treatment of alopecia areata (AA), there are few studies on efficacious combinations with
MG. This study was conducted to determine the efficacy and safety of MG plus 5% carpronium chloride (CC).
Methods: In the present interventional study, MG tablets plus 5% carpronium chloride (CC) were compared with
CC monotherapy in 31 patients with AA.
Results: There were no significant differences in efficacy between the two groups, and the AA area at 8 and 12
weeks was significantly reduced in both. The results of subanalysis stratified by the presence of allergic factors as
determined by IgE level showed that there were also significant decreases in the areas of AA 8 and 12 weeks after
the start of the combination therapy in patients with allergic factors (p<0.05). No serious adverse events were
observed in either group.
Conclusion: It is suggested that combination therapy with MG and CC has better therapeutic effects than CC
monotherapy, with a significant decrease in the area of AA from 4 weeks of treatment even in mild AA patients with
allergic factors.
Keywords: Alopecia areata; Glycyrrhizinate-glycine/DL-methionine
combination tablets; Carpronium chloride; Allergic factors; IgE
Introduction
Alopecia areata (AA) is the most frequent form of acquired
alopecia. It was reported that it has a 0.1-2% prevalence rate in the
USA, with a lifetime prevalence rate of 1.7%, and those figures are
estimated to be comparable in Japan [1,2]. This condition can occur in
all ethnic groups, genders, and age-groups. Recently, genes involved in
the development of AA have been identified. A tendency for AA to
occur in severe atopic dermatitis patients with filaggrin gene
abnormalities has been reported, a family history is often seen, and
therefore AA is considered to be a multifactorial genetic disease [3-5].
In addition, there is a high rate of concomitant atopic disease and
autoimmune disease [6-8]. Even in the initial stage of AA, some studies
found that the IgE level is elevated [9,10]. It is well known that
glycyrrhizin has antiinflammatory effects, and thus the effects of
monoammonium glycyrrhizinate/glycine/DL-methionine (MG) on
AA may be related to immunological activity. The hair follicle has
immunological privilege (IP) and is not susceptible to attack by normal
immunocompetent cells. Theoretically, the autoimmune reaction to
the hair follicle tissue due to the collapse of the IP is the main etiology
of AA, which can be triggered by widespread infection, autoimmune
disease, or psychological stress in those with a genetic predisposition to
develop it [11,12].
Various treatments for AA have been proposed, but many cases
relapse and/or prove refractory, and thus the establishment of
appropriate treatment is necessary. The Japanese Dermatological
Association Alopecia Areata Clinical Practice Guidelines were
proposed in 2010 and recommend treatment according to the severity
and stage of disease [13]. MG tablets have been used for the treatment
of AA for more than 50 years, and those guidelines state that they can
also be used in combined treatment. However, there are few detailed
reports on agents that can be combined with MG tablets for the
treatment of this condition. We therefore performed a preliminary
investigation of the appropriate use of MG tablets for the treatment of
AA and compared the efficacy and safety of combined treatment with
MG tablets and carpronium chloride (CC; Furozin) solution and
treatment with CC solution alone.
Patients and Methods
Outpatients with AA who met the following criteria were enrolled
in this study: five or fewer separate areas of hair loss or a hair loss area
of less than 25% of the scalp; and aged 20 years or older who gave
written informed consent for study participation. Exclusion criteria
were: severe dermatitis or eczema of the scalp; hair loss score of 3 or
more in the pull test; received oral, inhalation, or local-injection
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steroids or topical treatment of the scalp within 1 month prior to the
study; the use of agents to promote hair growth or prevent hair loss
within 1 month prior to the study; a history of allergy to glycyrrhizin
or carpronium; a diagnosis of malignancy; complications from severe
liver, kidney, or heart disease; pregnant, potentially pregnant, hoping to
become pregnant, or lactating during the study period; and deemed
ineligible by the attending physician for other reasons.
Eleven patients were assigned to the single-treatment group and 20
to the combined-treatment group using the minimization method to
ensure a balance between the two factors of age and number of areas of
hair loss. In the single-treatment group, the recommended dosage of
CC was applied to the affected area twice daily (morning and evening).
In the combined-treatment group, the recommended dosage of CC
solution was applied to the affected area twice daily (morning and
evening) and 3. It contains the components in one tablet.as
monoammonium glycyrrhizinate 35 mg (glycyrrhizinate 25 mg),
Glycine 25 mg, DL-methionine 25 mg. MG tablets were taken three
times daily (after meals). During the study period, the patients did not
receive any other drugs for the treatment of AA. In addition,
pharmaceutical products likely to induce hirsutism side effects such as
minoxidil, steroids, and cyclosporine; antiandrogenic agents such as
finasteride; antihistamines, other drugs, and quasi-drugs; and
cosmetics promoting hair growth or hair loss prevention were
prohibited.
For all patients, date of birth, gender, number of areas of hair loss,
size of areas of hair loss, results of the pull test, and second-degree
family history of AA or atopic predisposition were recorded in
addition to meeting the exclusion criteria and serum IgE levels. When
more than one area of hair loss was present, the area of maximum hair
loss was defined as the area for observation at the start of the study.
Item Comparison withstudy start Evaluation Score
Number of
areas of hair
loss
Increased Worsened -1
No change No change 0
Decreased Improved 1
Size of area
(area
observed) of
hair loss
Increased Worsened -1
No change No change 0
Decreased Improved 1
Disappeared Markedly improved 2
Degree of
hair
breakage
and
callous
Increased Worsened -1
No change No change 0
Decreased Improved 1
Disappeared Markedly improved 2
Terminal hair
growth
No Changing No change 0
Growing at low density Improved 1
Growing at high
density Markedly improved 2
Table 1: Physicians’ findings.
At the beginning of the study, and at 4, 8, and 12 weeks, the
attending physician recorded the number of areas of hair loss, size of
the areas, degree of hair breakage, and callous hair inside and outside
the observed areas, in addition to the growth of terminal hair. At each
evaluation visit, the attending physician compared the patients’
conditions with that at the beginning of treatment and assigned scores
(Table 1).
The areas observed were also photographed at each visit. The scores
at 4, 8, and 12 weeks were summed, and the treatment effect was
assessed as shown in Table 2. In addition, at 4, 8, and 12 weeks, the
attending physician asked all patients about their impressions of the
treatment effects compared with their conditions at the start of the
study, and their responses were recorded in the same six categories
(Table 3).
Evaluation Criteria Overview of effect
Worsened Total score –1 Progressive hair loss
No change Total score 0 No change
Slightly
improved Total score 1–2 Trend toward improvement
Moderately
improved Total score 3–4 Developing improvement
Markedly
improved Total score 5 Improvement
Not
determined Missing data
Table 2: Treatment effect evaluation.
At the eligibility survey, beginning of the study, and at 4, 8, and 12
weeks, the attending physician interviewed the patients on their
general health and recorded subjective symptoms and objective
findings reported. Pulse rates and blood pressure were measured, and
laboratory blood testing was performed at the beginning of the study
and at 12 weeks.
Evaluation Impression
Worsened Progressive hair loss
No change No change
Improved Terminal hair growth
Markedly improved Nearly recovered
Not determined Missing data
Table 3: Patients’ impression of treatment effects.
At 12 weeks, the attending physician made a comprehensive
evaluation of the six categories of treatment effects, taking into account
the patients’ own impressions, photographic evidence, the occurrence
of side effects, and other data including subjective symptoms, objective
findings, blood pressure, pulse rate, and blood test results. This
comprehensive evaluation was the primary endpoint of the study. The
safety evaluation was based on the incidence of adverse events
including abnormal changes in blood test results and side effects for
which a causal relationship with the study drugs could not be ruled
out. As the secondary endpoints, efficacy and safety were evaluated
Citation: Kubo Y, Nogita T, Kimura I, Chiba M, Sakakibara K (2016) Interventional Evaluation of Monoammonium Glycyrrhizinate-Glycine/DL-
Methionine Combination Tablets in Mild Alopecia Areata. J Clin Exp Dermatol Res 7: 322. doi:10.4172/2155-9554.1000322
Page 2 of 13
J Clin Exp Dermatol Res
ISSN:2155-9554 JCEDR an open access journal Volume 7 • Issue 1 • 1000322
separately. In addition, the reduction in areas of hair loss was evaluated
by measuring each area using Image J 1.47v software and comparing
them with the areas at the start of the study.
Statistical analysis
Statistical analyses of the comprehensive evaluation, patients’
impressions, and treatment effects were performed using Fisher’s exact
test on the results aggregated for the frequency of the categorical
variables in the contingency table. Changes in the area of hair loss and
physicians’ findings were compared in the rank-sum Wilcoxon test. In
the safety evaluation, the χ2 test was used to determine the incidence of
adverse events and Student’s t-test for blood test results, blood
pressure, and pulse rate changes. The statistical analysis software SAS
ver. 9.2 or later (SAS Institute, Cary, NC, USA) was used.
 
Single treatment  Combined treatment p-value Note
Average  SD  Average  SD -5  
  %    %   
Age 11 43.9 ± 11.2  20 42.7 ± 13.2 0.7909 1
Gender
Male  2  18.2   6  30
0.4634 2
Female  9  81.8   14  70
Number of areas of hair loss
Average 11 2.1 ± 1.6  20 1.4 ± 0.6 0.0681 1
1  7  63.6   14  70
0.039 3
2  0  0   5  25
3  1  9.1   1  5
4  2  18.2   0  0
5  1  9.1   0  0
Area of hair loss
<25  11  100   20  100
- 2
≥ 25  0  0   0  0
Pull test            
2  11  100   20  100
- 2
3  0  0   0  0
Family history of alopecia areata
Yes  2  18.2   4  20
0.9021 2
No  9  81.8   16  80
Atopic predisposition
Yes  4  36.4   4  20
0.3255 2
No  7  63.6   16  80
Lactating
No  9  81.8   14  70 - 4
Pregnant
No  9  81.8   14  70 - 4
History of oral steroid treatment
Yes  0  0   0  0 - 2
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No  11  100   20  100
Topical steroid treatment for alopecia areata
Yes  0  0   1  5
0.3442 2
No  11  100   19  95
Allergy to carpronium or glycyrrhizin
Yes  0  0   0  0
- 2
No  11  100   20  100
Dermatitis and eczema on scalp
Yes  0  0   0  0
- 2
No  11  100   20  100
Diagnosis of malignancy
Yes  0  0   0  0
- 2
No  11  100   20  100
Severe liver, kidney, or heart disease
Yes  0  0   0  0
- 2
No  11  100   20  100
Concomitant drug
Yes  0  0   4  20
0.0505 2
No  11  100   16  80
IgE RIST  117.4 ± 156.4   218.2 ± 391.6 0.4225 1
Notes
1. Comparison between groups using Student’s t-test.
2. Comparison between groups using the χ2 test.
3. Comparison between groups using Fisher’s exact test.
4. Women only.
5. -, p-value not calculated.
Table 4: Patient characteristics.
Result
Patient characteristics
The characteristics of patients are shown in Table 4. The single-
treatment group had more areas of hair loss than the combined-
treatment group at the start of the study (p=0.0390). Four patients in
the combined-treatment group had received drugs other than the
study drugs (p=0.0505). No significant differences were found in other
characteristics between the two groups.
Evaluation
Single treatment Combined treatment p-value
n % n %
Markedly improved 4 36.4 4 21.1
0.7954Moderately improved 3 27.3 8 42.1
Slightly improved 4 36.4 5 26.3
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No change 0 0 1 5.3
Worsened 0 0 1 5.3
Not determined 0 0 0 0
Total 11 100 19 100 -
Table 5: Comprehensive evaluation. Comparison between groups using Fisher’s exact test.
Efficacy evaluation (primary endpoint)
The comprehensive evaluation results evaluated by the attending
physicians (11 patients in the single-treatment group and 19 in the
combined-treatment group after 2 dropped out of the study after 8
weeks) are shown in Table 5. No significant difference between the two
groups was seen. Seven of 11 patients (63.6%) in the single-treatment
group and 12 of 19 (63.2%) in the combined-treatment group showed
moderate or greater improvement.
 4 weeks 8 weeks 12 weeks
Single Treatment
 n % n % n %
Yes 1 9.1 0 0 0 0
No 10 90.9 11 100 11 100
Combined Treatment
Total 11 100 11 100 11 100
Yes 3 15.8 1 5.9 0 0
No 16 84.2 16 94.1 17 100
 Total 19 100 17 100 17 100
p-value 0.5939 0.3121 -
Table 6: Adverse events during the study period [Comparison between groups using the χ2 test].
Safety evaluation (primary endpoint)
The number and incidence rate of adverse events at 4, 8, and 12
weeks; the number and incidence rate of subjective symptoms and
objective findings; and the blood test results at the beginning of the
study and at 12 weeks are shown in Tables 6-9, respectively. Seven
adverse events (1 in the single-treatment and 6 in the combined-
treatment groups) occurred in 5 patients (1 in the single-treatment
group and 4 in the combined-treatment groups), and a causal
relationship with the study drugs could not be ruled out in 3 of those
adverse events (all in the combined-treatment group). The 3 adverse
events that were possibly associated with the study drugs were 2
episodes of headache and 1 of itching at the topical application site.
The symptoms were mild, and all patients recovered.
 Start 4 weeks 8 weeks 12 weeks
  n % n % n % n %
Single
treatment
 
 
Yes 0 0 0 0 0 0 0 0
No 11 100 11 100 11 100 11 100
Total 11 100 11 100 11 100 11 100
Combined
Treatment
Yes 1 5 2 10.5 1 5.9 1 5.9
No 19 95 17 89.5 16 94.1 16 94.1
 Total 20 100 19 100 17 100 17 100
p-value 0.3442 0.1671 0.3121 0.3121
Table 7: Subjective symptoms reported [Comparison between groups using the χ2 test].
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Three patients dropped out of the study, 1 after 4 weeks and 2 after 8
weeks. The compliance of other patients was good, with no deviation
in dosage and administration. Data on the patients who dropped out
were aggregated and treated as missing values.
 Start 4 weeks 8 weeks 12 weeks
Single  n % n % n % n %
treatment Yes 0 0 0 0 0 0 0 0
 No 11 100 11 100 11 100 11 100
 Total 11 100 11 100 11 100 11 100
Combined  n % n % n % n %
treatment Yes 1 5 1 5.3 1 5.9 0 0
 No 19 95 18 94.7 16 94.1 17 100
p-value 0.3442 0.334 0.3121
Table 8: Objective findings [Comparison between groups using the χ2 test].
Changes in findings, treatment evaluation, and patient
impressions (secondary endpoints)
Changes in physicians’ findings, evaluation of treatment, and
patients’ impressions at 4, 8, and 12 weeks compared with those at the
start of study are shown in Tables 10-12, respectively. No significant
differences between the two groups were seen throughout the study
period.
Single treatment
Item
Start 12 weeks  
n Ave. ± SD n Ave. ± SD p-value1
SBP 11 115.5 ± 27.1 11 112.3 ± 18.6 0.508
DBP 11 74.3 ± 16.3 11 72.6 ± 12.5 0.6382
Puls 11 73.3 ± 11 11 69.7 ± 12.9 0.3365
BUN 11 14 ± 4.9 11 13.3 ± 2.8 0.5577
CRE 11 0.64 ± 0.09 11 0.65 ± 0.1 0.4579
AST 11 19 ± 3.4 11 19.2 ± 4.8 0.8591
ALT 11 16 ± 4.4 11 17.2 ± 4.1 0.4802
ALP 11 189 ± 28.8 11 185.5 ± 36.1 0.556
LDH 11 193.3 ± 61.6 11 182.1 ± 29.4 0.4305
γ-GTP 11 22 ± 10 11 19.7 ± 7.8 0.203
CRP 11 0.05 ± 0.03 11 0.08 ± 0.09 0.2745
WBC 11 6554.5 ± 1465.9 11 5990.9 ± 1363.4 0.1034
RBC 11 451.2 ± 41.9 11 450.6 ± 41.1 0.9334
Hgb 11 13.8 ± 1.3 11 13.7 ± 1.2 0.6116
PLT 11 26.9 ± 6 11 25.5 ± 6.2 0.242
 11 100 ± 0 11 100 ± 0 -
Eos 11 1 ± 1 11 0.8 ± 0.8 0.6761
Baso 11 2.1 ± 1.8 11 3 ± 2.6 0.4171
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Neut-Stab 11 2 ± 1 11 1.6 ± 0.8 0.3705
Neut-Seg 11 58.9 ± 11.1 11 50.8 ± 6 0.0569
Ly 11 32 ± 9.1 11 37.9 ± 7 0.1246
Mono 11 4 ± 2.3 11 5.8 ± 3.7 0.1852
Table 9: (a) Showing single treatment blood test results.
Combined treatment
Item
Start 12 weeks Abort  
n Ave. ± SD n Ave. ± SD n Ave. ± SD p-value1
SBP 20 118.2 ± 24.1 17 117.2 ± 13.7 2 127 ± 32.5 0.687
DBP 20 77.5 ± 15.1 17 76.6 ± 13.9 2 72.5 ± 3.5 0.777
Puls 20 76.2 ± 14.4 17 75.4 ± 11.5 2 66 ± 5.7 0.8455
BUN 20 14.5 ± 3.1 17 13.6 ± 3.1 2 10.5 ± 3.5 0.1762
CRE 20 0.67 ± 0.1 17 0.72 ± 0.14 2 0.6 ± 0.1 0.003
AST 20 22.8 ± 9.2 17 21.9 ± 11.8 2 19 ± 1.4 0.1441
ALT 20 23.2 ± 15 17 23.9 ± 20.1 2 13 ± 1.4 0.6551
ALP 20 188.6 ± 38.6 17 195.2 ± 37 2 191 ± 67.9 0.3037
LDH 20 168.7 ± 29.2 17 174.7 ± 27.5 2 173.5 ± 33.2 0.6236
γ-GTP 20 29 ± 25.3 17 29.5 ± 24.8 2 14.5 ± 3.5 0.3906
CRP 20 0.07 ± 0.08 17 0.08 ± 0.09 2 0.04 ± 0.01 0.4484
WBC 20 5315 ± 1458.3 17 5705.9 ± 2011.7 2 4050 ± 1343.5 0.4471
RBC 20 450.2 ± 51 17 454.9 ± 57.5 2 428.5 ± 26.2 0.8707
Hgb 20 13.5 ± 1.5 17 13.6 ± 1.6 2 13.4 ± 1.8 0.7747
PLT 20 24.2 ± 4.2 17 24.2 ± 5 2 25.4 ± 3 0.8832
20 100 ± 0 17 100 ± 0 2 100 ± 0 -
Eos 20 0.9 ± 0.9 17 0.8 ± 0.9 2 2 ± 1.4 0.8899
Baso 20 2.7 ± 2.2 17 4.9 ± 4.3 2 5 ± 7.1 0.0765
Neut 1 55.1 - - - - - - -
Neut-Stab 19 1.5 ± 0.6 16 1.6 ± 0.7 2 2 ± 0 0.5805
Neut-Seg 19 56.5 ± 7.8 16 53.8 ± 8.1 2 55.5 ± 12 0.3085
Ly 20 33.9 ± 7.7 17 33.6 ± 6.9 2 30.5 ± 4.9 0.897
Mono 20 4.8 ± 2.3 17 5 ± 1.6 2 5 ± 1.4 0.6925
1. Comparison between start and 12 weeks within each group using the paired t-test.
2. Comparison between groups using the paired t-test (start).
3. Comparison between groups using the paired t-test (12 weeks).
Table 9: (b) Showing combined treatment blood test results.
Between groups p-value2 p-value3
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0.7848 0.4283
0.5895 0.4446
0.5636 0.2387
0.753 0.7507
0.4678 0.1632
0.2019 0.4712
0.1326 0.2837
0.9763 0.497
0.1407 0.5051
0.3886 0.2207
0.5107 0.9164
0.0315 0.6841
0.9548 0.8339
0.5729 0.7551
0.1522 0.5415
- -
0.7063 0.9869
0.4681 0.2024
- -
0.0832 0.8063
0.4943 0.306
0.5516 0.119
0.378 0.4285
Table 9: Blood test results.
Changes in areas of hair loss (secondary endpoint)
Areas of hair loss at 4, 8, and 12 weeks in 11 patients in the single-
treatment group and 17 in the combined-treatment group, excluding
the patients who dropped out, were compared with the areas at the
start of the study. No significant difference was seen between the two
groups. Although no reduction in the size of areas of hair loss was
observed in the single-treatment group at any time point, a reduction
was observed in the combined-treatment group at 4 weeks and
thereafter (Table 13 and Figure 1).
In patients with allergic factors, as indicated by “IgE ≥ 171” in Table
14, comprising 6 in the single-treatment group and 7 in the combined-
treatment group, the areas of hair loss at each observation were
compared with those at the start of the study. In the combined-
treatment group, the areas of hair loss at 8 and 12 weeks were reduced
significantly (both p<0.05, Table 14, Figure 1).
Figure 1: Change in size of areas of hair loss in patients with atopic predispositions in the combined-treatment and single-treatment groups at
the start of the study and at 12 weeks.
Discussion
The Alopecia Areata Clinical Practice Guidelines were formulated
based on the results of extensive clinical practice and other
recommendations [11]. However, additional treatment options are
required because the condition has a major effect on patients’ quality of
life, refractory and recurrent cases are common, and regeneration of
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the hair may take a long time. MG tablets have been used widely for
many years in treating AA and are recommended as combined therapy
in the clinical practice guidelines. This study investigated combined
treatment with MG tablets and CC solution. It was reported that this
combination showed efficacy in 60% of AA patients with moderate or
more severe disease [14]. However, no randomized, controlled study
evaluating the efficacy of MG tablets has been conducted, as pointed
out in the guidelines.
Start to 4 weeks
Single treatment Combined treatment p-value
Items n Ave. SD Median n Ave. SD Median
Number of areas of hair loss 11 0 ± 0 0 19 -0.1 ± 0.2 0 0.4891
Size of area of hair loss 11 0.4 ± 0.8 1 19 0.1 ± 0.6 0 0.2413
Hair breakage and callous 11 0.5 ± 0.7 0 19 0.2 ± 0.4 0 0.3283
Terminal hair growth 11 0.8 ± 0.6 1 19 0.7 ± 0.7 1 0.7149
Total score 11 1.6 ± 1.6 2 19 1 ± 1.2 1 0.3149
Start to 8 weeks
Number of areas of hair loss 11 0 ± 0 0 17 0.1 ± 0.4 0 0.6613
Size of area of hair loss 11 0.9 ± 0.3 1 17 0.6 ± 0.8 1 0.236
Hair breakage and callous 11 0.5 ± 0.7 0 17 0.6 ± 0.6 1 0.3565
Terminal hair growth 11 1.4 ± 0.7 1 17 1.1 ± 0.7 1 0.3655
Total score 11 2.7 ± 1.1 3 17 2.4 ± 1.9 2 0.5755
Start to 12 weeks
Number of areas of hair loss 11 0.4 ± 0.5 0 17 0.3 ± 0.7 0 0.9155
Size of area of hair loss 11 1.3 ± 0.6 1 17 0.9 ± 1 1 0.4417
Hair breakage and callous 11 1.2 ± 0.9 1 17 1.1 ± 0.9 1 0.8603
Terminal hair growth 11 1.3 ± 0.8 1 17 1.2 ± 0.7 1 0.8371
Total score 11 4.1 ± 2.6 3 17 3.6 ± 2.6 3 0.7558
Table 10: Physicians’ findings [Comparison between groups using the Wilcoxon rank-sum test].
Therefore, we compared the effectiveness of MG tablets alone with
the combination of MG tablets and CC solution. No significant
differences in efficacy, clinical findings, and patients’ impressions of
efficacy were observed between the two groups. A significant reduction
in areas of hair loss was not observed in the single-treatment group but
was observed in the combined treatment group at 4 weeks and
thereafter. This result may have been due to the difference in the
number of patients (11 versus 17) in the two groups. No serious
adverse events occurred during the study, and the incidence of adverse
events in the two groups did not differ significantly.
It has been reported that the IgE level as an allergic factor is elevated
in the early stage of AA [15] .Therefore we conducted an analysis by
allergic factors. The area of AA was significantly decreased in patients
with allergic factors 8 and 12 weeks after treatment as compared with
baseline, while a reduction in the AA area was observed in patients
without allergic factors but was not significant.
4 weeks
 Single treatment Combined treatment p-value
Evaluation n % n %  
Worsened 1 9.1 2 10.5
0.8064
No change 2 18.2 6 31.6
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Slightly improved 6 54.5 9 47.4
Moderately improved 1 9.1 2 10.5
Markedly improved 1 9.1 0 0
Total 11 100 19 100 -
8 weeks
Worsened 0 0 1 5.9
0.8539
No change 0 0 2 11.8
Slightly improved 5 45.5 6 35.3
Moderately improved 5 45.5 6 35.3
Markedly improved 1 9.1 2 11.8
Total 11 100 17 100 -
12 weeks 
Worsened 0 0 2 11.8
0.6644
No change 1 9.1 0 0
Slightly improved 2 18.2 3 17.6
Moderately improved 3 27.3 6 35.3
Markedly improved 5 45.5 6 35.3
Total 11 100 17 100 -
Table 11: Treatment evaluation [Comparison between groups using Fisher’s exact test].
It was shown in vitro that glycyrrhizin acid, which is the active
ingredient in MG tablets, is hydrolyzed by β-D-glucuronidase and
metabolized to glycyrrhetinic acid [16,17]. Since glycyrrhetinic acid
has an inhibitory effect on 11β-HSD2, the enzyme that metabolizes
inactive cortisone to cortisol, it is possible that the antiinflammatory
effects of cortisol in the body are indirectly affected by glycyrrhetinic
acid, resulting in improved AA [18].
 Single treatment Combined treatment p-value
Evaluation n % n %
4 weeks      
Worsened 0 0 2 10.5
0.5851
No change 6 54.5 6 31.6
Improved 5 45.5 10 52.6
Markedly improved 0 0 1 5.3
Not determined 0 0 0 0
Total 11 100 19 100 -
8 weeks      
Worsened 0 0 1 5.9
0.6832No change 1 9.1 4 23.5
Improved 9 81.8 10 58.8
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Markedly improved 1 9.1 2 11.8
Not determined 0 0 0 0
Total 11 100 17 100 -
12 weeks     
Worsened 0 0 0 0
0.7005
No change 3 27.3 4 23.5
Improved 4 36.4 4 23.5
Markedly improved 4 36.4 9 52.9
Not determined 0 0 0 0
Total 11 100 17 100 -
Table 12: Patients’ impression of treatment effect [Comparison between groups using Fisher’s exact test].
When steroids are administered by local injection, Samrao et al.
recommended monitoring the bone mineral density (BMD) of AA
patients to avoid the risk of steroidal osteoporosis because they found
abnormal BMD in 50% of patients after 20 weeks or longer treatment
with triamcinolone acetonide in 4-8 week cycles and because the
cumulative dose of triamcinolone acetonide is a risk factor for steroidal
osteoporosis [18]. On the other hand, it was reported that glycyrrhizic
acid prevents steroid-induced osteoporosis in rats [19]. Glycyrrhetinic
acid was reported to inhibit 11β-HSD1 of the enzyme metabolizing
cortisone to cortisol [20], and thus it was inferred that glycyrrhetinic
acid prevents osteoporosis by promoting the metabolism of cortisol
produced in excess due to steroid treatment. In other words,
glycyrrhetinic acid acts on both the enzyme that activates and the
enzyme that inactivates cortisol and plays a role in the treatment of AA
by promoting cortisol production when the response to corticotropin-
releasing hormone is decreased. Glycyrrhetinic acid also prevents side
effects by increasing the metabolism of excess cortisol produced in
response to steroid administration.
Average area (cm2)
 n Start 4 weeks 8 weeks 12 weeks
Single treatment 11 1.85 ± 1.22 1.44 ± 1.15 1.08 ± 0.95 0.89 ± 1.24
p-value (within group)*  0.1581 0.126 0.0966
Combined treatment 17 2.63 ± 2.78 2.06 ± 2.54 1.56 ± 2.25 0.95 ± 1.54
p-value (within group)*  0.0387 0.0078 0.0009
p-value (between groups)**  0.7419 0.7598 0.9064 1
Reduction rate (%)
Single treatment     -20.84 ± 29.56 -35.88 ± 40.64 -46.64 ± 55.84
Combined treatment     -15.83 ± 41.91 -45.79 ± 37.25 -61.12 ± 48.57
p-value (between groups)**   0.8323 0.4659 0.6592
*Comparison wihin each group using the Bonferroni multiple procedure.
**Comparison between groups using Wilcoxon’s exact test.
Table 13: Change in area (area observed) of hair loss.
Since it has been recognized that the serum oxidative stress marker
level is higher and the antioxidative stress marker is lower in AA
patients in than in healthy people, it was suggested that oxidative stress
is involved in the development of the condition [21,22]. Glycyrrhizic
acid is known to exert antioxidative effects [23-25], suggesting that it
could improve symptoms by decreasing oxidative stress in AA.
CC hydrate, the active ingredient in CC solution, has local
vasodilator activity, increasing blood flow in capillaries and promoting
local metabolism by stimulating acetylcholine receptors of vascular
smooth muscle. CC hydrate promotes hair growth by acting on
degraded hair follicles [26,27].
Among the various treatments for AA, steroids have been
administered most frequently because their mechanism of action is
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clear. However, many patients have reservations about steroid
treatment even under the supervision of a physician. MG tablets are
viewed as safe in terms of both lack of side effects and treatment
efficacy and they contribute to the maintenance of homeostasis of
corticosteroids in hair follicle tissue.
Average area (cm2)
n Start 4 weeks 8 weeks 12 weeks
Single treatment 6 2.11 ± 1.52 1.63 ± 1.53 1.3 ± 1.26 1.17 ± 1.62
p-value (within group)* 0.6564 0.4689 0.6564
Combined treatment 7 2.95 ± 3.84 2.34 ± 3.45 1.27 ± 2 0.46 ± 0.69
p-value (within group)* 0.3282 0.0468 0.0468
p-value (between
groups)** 1 0.6682 0.5677 0.7072
Reduction rate (%)
Single treatment -22.62 ± 34.48 -41.53 ± 35.08 -45.32 ± 66.18
Combined treatment -26.84 ± 30.3 -65.80 ± 20.02 -86.76 ± 13
p-value (between groups)** 1 0.0865 0.4989
*Comparison within each group using the Bonferroni multiple procedure.
**Comparison between groups using Wilcoxon’s exact test.
Table 14: Change in area (area observed) of hair loss in patients with atopic predisposition.
The limitations of this study were, because it was an interventional
comparison, the number of patients differed between the two groups,
and the overall sample size was small. Therefore, no statistically
significant difference was seen between groups. Since the present
combination therapy obviously showed the decrease in the area of AA
and the effects in patients with allergic factors, we proceed to further
larger randomized trials to confirm the results in this study.
In conclusion, in the present interventional study, MG tablets
combined with CC solution therapy showed decreases in areas of AA
without serious adverse events, especially in patients with allergic
factors.
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